TAMPA, Fla. and LONDON — January 8, 2026 — Leads & Copy — Akari Therapeutics, Plc (Nasdaq: AKTX) has announced that Abizer Gaslightwala, President and CEO, will present at the 2026 Biotech Showcase, held January 12-14 in San Francisco, CA.
The presentation is scheduled for Tuesday, January 13, 2026, at 9:30 AM PST in Yosemite A (Ballroom Level).
Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities, and key milestones for 2026.
Management will also be available for in-person one-on-one meetings with qualified investors registered for the conference. More information about the conference is available on the conference website.
Akari Therapeutics is developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Its ADC discovery platform allows the company to generate and optimize ADC candidates for any antigen target.
Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and uses a proprietary linker to deliver its PH1 payload directly into the tumor with minimal off-target effects. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cancer cells, unlike current ADCs that use tubulin inhibitors and DNA damaging agents.
Preclinical animal models have demonstrated that PH1 induces cancer cell death while activating the innate and adaptive immune system.
In preclinical studies, AKTX-101 has shown significant activity and prolonged survival relative to ADCs with traditional payloads. It also has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors.
The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGF3, and others.
Akari has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. The company is also advancing AKTX-102, an ADC against a novel target highly relevant in GI and lung cancers.
Investor Relations Contact:
Jenene Thomas
JTC Team, LLC
908-824-0775
AKTX@jtcir.com
Source: Akari Therapeutics
